>…makes it interesting for the partnership deal here at US for HD indication alone, where GTCB should have much better share in the profits.<
Compared to the partnership with Leo, GTC should get a bigger share of the profits in the deal to be struck with a US ATryn partner. However, the HD indication is still a relatively small slice of the ATryn pie, even in the US, and it’s clear that the main commercial interest of the US ATryn partner will be the DIC indication.
Here are some excerpts from Dr Cox’s remarks during the 3Q07 CC [#msg-24216158, emphasis added]:
>> …We believe the U.S.A. to be a major untapped potential for ATryn since there is a very limited competition from the existing plasma-derived product. As in Europe, the key to unlocking this potential is the continuing development of ATryn in acquired deficiency indications. In the case of DIC… we believe the market opportunity in the U.S.A. alone to be in the range of $2 billion to $3 billion.
…We would certainly be licensing a partner for the commercialization of ATryn, initially, in the hereditary deficiency indication. But in these negotiations, we are specifically requiring that our partners support the development in the broader acquired deficiency indications… <<
Market Data 
Markets 
AI
